⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCRX News
BioCryst Pharmaceuticals Inc
Anti-GPC3 Targeted Therapies Market Poised for Growth Through 2040 as Expanding Patient Populations and Competitive Innovation Unlock New Opportunities
globenewswire.com
AZN
BCRX
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
prnewswire.com
BCRX
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio
globenewswire.com
BCRX
BioCryst to Present at Upcoming Investor Conference
globenewswire.com
BCRX
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
globenewswire.com
BCRX
Amplifica Appoints Hans Hofland, Ph.D., as Chief Development Officer and William Humphries to Board of Directors
prnewswire.com
ACRS
ALC
AMGN
BCRX
BIIB
BMY
CRSP
CTRA
CYTK
DASH
EXAS
GILD
GSK
INCY
JNJ
KDP
LULU
MRNA
NBIX
NVS
OCGN
ORCL
PFE
REGN
ROST
RVMD
SNOW
SRPT
STRL
TGTX
TMO
TRMB
TSLA
TXG
VRTX
XOM
ZBRA
Sleep as a Window into Early Stages of Alzheimer's Pathophysiology: Implications for Clinical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
BCRX
ALKS
LLY
BIIB
ABBV
Nitrase Therapeutics Announces the Appointment of Three Industry Veterans to Its Board of Directors
globenewswire.com
ABBV
BCRX
K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing
globenewswire.com
BCRX
Form 8-K
sec.gov
BCRX